Cargando…
Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834586/ https://www.ncbi.nlm.nih.gov/pubmed/36644181 http://dx.doi.org/10.21037/tcr-22-2429 |
| _version_ | 1784868493911392256 |
|---|---|
| author | Gower, Arjan Garon, Edward B. |
| author_facet | Gower, Arjan Garon, Edward B. |
| author_sort | Gower, Arjan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9834586 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98345862023-01-13 Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments Gower, Arjan Garon, Edward B. Transl Cancer Res Editorial Commentary AME Publishing Company 2022-12 /pmc/articles/PMC9834586/ /pubmed/36644181 http://dx.doi.org/10.21037/tcr-22-2429 Text en 2022 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Gower, Arjan Garon, Edward B. Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title | Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title_full | Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title_fullStr | Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title_full_unstemmed | Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title_short | Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| title_sort | pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834586/ https://www.ncbi.nlm.nih.gov/pubmed/36644181 http://dx.doi.org/10.21037/tcr-22-2429 |
| work_keys_str_mv | AT gowerarjan pembrolizumabinadvancednonsmallcelllungcancersafetyimplicationsofdoseadjustments AT garonedwardb pembrolizumabinadvancednonsmallcelllungcancersafetyimplicationsofdoseadjustments |